Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07691424
Starting soon Observational

Impact of Migration History and Social Conditions on the Immuno-virological Control of HIV in Migrants in France

NCT07691424 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Clermont-Ferrand
Phase
Observational
Started
2026-07-15
Last updated
2026-07-08

Condition(s) studied

HIV - Human Immunodeficiency VirusSocio-economic StatusMigrants

Study summary

Migrants living with HIV - whether the infection was diagnosed in their country of origin or in France- frequently experience vulnerabilities related to their migration trajectories and often face socioeconomic and administrative instability upon arrival .

The primary outcome of this study is to compare the immunovirological efficacy of antiretroviral therapy among migrants living with HIV patients according to their social and administrative status.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults (≥18 years of age); * Migrant patients (i.e., individuals who entered France for the first time from another country) receiving care at Clermont-Ferrand University Hospital between January 1, 2010, and December 31, 2022, whose HIV infection was either known at the time of their arrival in France or diagnosed within 12 months after their arrival in France. Non-inclusion Criteria: * Patients who declined to participate in the study; * Patients who do not speak French and for whom no interpretere was available * Adults subject to a legal protection measure (i.e., under guardianship, curatorship, or judicial protection)

Primary outcome measure(s)

  • HIV immuno-virological status — Submission to the Research Ethics Committee (REC): February 2026 REC approval: May 2026 Study initiation : July 2026 Recruitment period: 18 months Total study duration: 30 months Estimated study completed : january 2029
    To compare the immuno-virological efficacy of antiretroviral therapy according to the social and administrative status of HIV-infected migrants

Trial sites (1)

FacilityCityRegionStatus
Clermont-Ferrand University Hospital Clermont-Ferrand France

More University Hospital, Clermont-Ferrand trials in France

Vulnerability and Risk of Neuropathic Pain in Cancer Recruiting
Helping Osteoarthritis Patients to Walk With NSAID Recruiting
Ketoanalogue Supplementation for Muscle Protection in CKD 4 and 5 Patients With Moderately Low Protein Diet (KETO-PROT-ACTION) Recruiting
CARPEUS : Effect of Carvedilol on the Portosystemic Gradient as Measured by Endoscopic Ultrasound Recruiting
Neurosensorial Disorder and Pain in Oral Cavity and Oropharynx Cancer Traited Patients (OCAPA) Recruiting

Other trials for the same condition

Sexual Health of Sub-Saharan African Migrant Women Recently Diagnosed With HIV in Île-de-France: Missed Opportunities for Prevention Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07691424 on ClinicalTrials.gov ↗ ← All trials in France